WO 03/103743 PCT/US03/18059

## CLAIMS

5

10

15

20

1. A device comprising a drug delivery system for implantation in a lumen of a physiologic conduit and an amount of a pharmaceutical agent effective to treat a condition responsive to the drug proximal to the physiologic conduit and/or distal to the physiologic conduit.

- 2. The device according to claim 1, wherein the delivery system is a stent or catheter.
- 3. The device according to claim 1, wherein the physiologic conduit is selected from the group consisting of artery, pancreatic duct, ureter, urethra, bile duct and spinal column.
- 4. The device according to claim 3, wherein the blood vessel is pulmonary, cranial, femoral, or coronary.
- 5. The device according to claim 1, wherein the drug is a vasodilator or chemotherapeutic.
- 6. The device according to claim 5, wherein the vasodilator is selected from the group consisting of vasoactive intestinal peptide (VIP) or neuropeptide (NP).
  - 7. The device according to claim 6, wherein the vasodilator is present in an amount effective to inhibit restenosis.
- 8. The device according to claim 6, wherein the vasodilator is present in an amount effective to increase blood flow proximal to and distal to the site of implantation.
- 9. The device according to claim 6, wherein the vasodilator is VIP and is present in an amount of from about 1 µg to 500 µg.
- The device according to claim 6, wherein the vasodilator is NP and is
  present in an amount or from about 1 μg to 500 μg.
  - 11. The device according to claim 5 for treatment of pulmonary hypertension.
  - 12. The device according to claim 6 for the treatment of decreased blood flow through a blood vessel.
- 30 13. The device according to claim 12, wherein the decreased blood flow is due to restenosis.
  - 14. The device according to claim 12, wherein the decreased blood flow is due to pulmonary hypertension.

WO 03/103743 PCT/US03/18059

15. The device according to claim 12, wherein the decreased blood flow is due to diabetes.

- 16. The device according to claim 5, wherein the pharmaceutical agent is a chemotherapeutic.
- 17. The device according to claim 16 wherein the chemotherapeutic is selected from the group consisting of vinca alkaloids such as the vinblastine, vincristine and vindesine sulfates, adriamycin, bleomycin sulfate, carboplatin, cisplatin, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, duanorubicin hydrochloride, doxorubicin hydrochloride, etoposide, fluorouracil, lomustine, mechlororethamine hydrochloride, melphalan, mercaptopurine, methotrexate, mitomycin, mitotane, pentostatin, pipobroman, procarbaze hydrochloride, streptozotocin, taxol, thioguanine, uracil mustard and anti-cancer antibodies.
- 18. The device according to claim 17, wherein the device is implanted proximal to a tumor.
- 19. The device according to claim 18, wherein the tumor is selected from the group consisting of astrocytoma, oligodendroglioma, ependymoma, medulloblastoma, primitive neural ectodermal tumor (PNET), pancreatic ductal adenocarcinoma, small and large cell lung adenocarcinomas, squamous cell carcinoma, bronchoalveolarcarcinoma, epithelial adenocarcinoma, and liver metastases thereof, hepatoma, cholangiocarcinoma, breast tumors such as ductal and lobular adenocarcinoma, squamous and adenocarcinomas of the uterine cervix, uterine and ovarian epithelial carcinomas, prostatic adenocarcinomas, transitional squamous cell carcinoma of the bladder, soft tissue sarcomas and leiomyosarcomas.
- 20. The device according to claim 1, wherein the drug is coated on the delivery system.
- 21. The device according to claim 1, wherein the drug is impregnated into the delivery system.
- 22. The device according to claim 1, wherein the device is biodegradable or bioresorbable.

25

5

10

15

20